Oxford BioMedica (GB:OXB) has released an update.
Oxford Biomedica, a leading cell and gene therapy CDMO, has applied for a block listing of 100,000 ordinary shares on the Premium segment of the Official List and the London Stock Exchange. The shares, linked to the company’s Long Term Incentive Plan, are set to be admitted on July 26, 2024, and will rank equally with existing shares. This move underscores the company’s growth and commitment to enabling the delivery of life-changing therapies.
For further insights into GB:OXB stock, check out TipRanks’ Stock Analysis page.
